Skip to main content

Closed

MAZE: Maze Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin-670.3%

ROIC-33.2%

Financially safe

Stretched

Debt / equity0.18×

Interest coverage-154.8×

Current ratio17.88×

Maze Therapeutics, Inc.

MAZENASDAQ·USD·Closed

Maze Therapeutics, Inc.

MAZENASDAQ·USD·Closed

$26.92

−2.57%

$26.92

−$0.71 (2.57%)

52W Range

35thpctl

Volume

0.56×avg

Mkt Cap

1.49BUSD

P/E

-9.8TTM

Div Yield

–ann

52W Range

35thpctl

Volume

0.56×avg

Market Cap

1.49BUSD

P/E Ratio

-9.8TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings